scholarly journals Associations Between Cytokine Genes and a Symptom Cluster of Pain, Fatigue, Sleep Disturbance, and Depression in Patients Prior to Breast Cancer Surgery

2014 ◽  
Vol 17 (3) ◽  
pp. 237-247 ◽  
Author(s):  
Sy-Huey Doong ◽  
Anand Dhruva ◽  
Laura B. Dunn ◽  
Claudia West ◽  
Steven M. Paul ◽  
...  

Pain, fatigue, sleep disturbance, and depression are common and frequently co-occurring symptoms in oncology patients. This symptom cluster is often attributed to the release of proinflammatory cytokines. The purposes of this study were to determine whether distinct latent classes of patients with breast cancer ( n = 398) could be identified based on their experience with this symptom cluster, whether patients in these latent classes differed on demographic and clinical characteristics and whether variations in cytokine genes were associated with latent class membership. Three distinct latent classes were identified: “all low” (61.0%), “low pain and high fatigue” (31.6%), “all high” (7.1%). Compared to patients in the all low class, patients in the all high class were significantly younger, had less education, were more likely to be non-White, had a lower annual income, were more likely to live alone, had a lower functional status, had a higher comorbidity score, and had more advanced disease. Significant associations were found between interleukin 6 (IL6) rs2069845, IL13 rs1295686, and tumor necrosis factor alpha rs18800610 and latent class membership. Findings suggest that variations in pro- and anti-inflammatory cytokine genes are associated with this symptom cluster in breast cancer patients.

2019 ◽  
Vol 28 (2) ◽  
pp. 845-855 ◽  
Author(s):  
Rina S. Fox ◽  
Sonia Ancoli-Israel ◽  
Scott C. Roesch ◽  
Erin L. Merz ◽  
Sarah D. Mills ◽  
...  

Cancers ◽  
2021 ◽  
Vol 13 (14) ◽  
pp. 3390
Author(s):  
Mats Enlund

Retrospective studies indicate that cancer survival may be affected by the anaesthetic technique. Propofol seems to be a better choice than volatile anaesthetics, such as sevoflurane. The first two retrospective studies suggested better long-term survival with propofol, but not for breast cancer. Subsequent retrospective studies from Asia indicated the same. When data from seven Swedish hospitals were analysed, including 6305 breast cancer patients, different analyses gave different results, from a non-significant difference in survival to a remarkably large difference in favour of propofol, an illustration of the innate weakness in the retrospective design. The largest randomised clinical trial, registered on clinicaltrial.gov, with survival as an outcome is the Cancer and Anesthesia study. Patients are here randomised to propofol or sevoflurane. The inclusion of patients with breast cancer was completed in autumn 2017. Delayed by the pandemic, one-year survival data for the cohort were presented in November 2020. Due to the extremely good short-term survival for breast cancer, one-year survival is of less interest for this disease. As the inclusions took almost five years, there was also a trend to observe. Unsurprisingly, no difference was found in one-year survival between the two groups, and the trend indicated no difference either.


The Breast ◽  
2013 ◽  
Vol 22 (3) ◽  
pp. 273-276 ◽  
Author(s):  
Christina Van Onselen ◽  
Bradley E. Aouizerat ◽  
Laura B. Dunn ◽  
Steven M. Paul ◽  
Claudia West ◽  
...  

2012 ◽  
Vol 20 (10) ◽  
pp. 2611-2619 ◽  
Author(s):  
Christina Van Onselen ◽  
Bruce A. Cooper ◽  
Kathryn Lee ◽  
Laura Dunn ◽  
Bradley E. Aouizerat ◽  
...  

Breast Care ◽  
2017 ◽  
Vol 12 (6) ◽  
pp. 385-390 ◽  
Author(s):  
Fabian Riedel ◽  
André Hennigs ◽  
Sarah Hug ◽  
Benedikt Schaefgen ◽  
Christof Sohn ◽  
...  

Aim: To describe and discuss the evidence for oncological safety of different procedures in oncological breast surgery, i.e. breast-conserving treatment versus mastectomy. Methods: Literature review and discussion. Results: Oncological safety in breast cancer surgery has many dimensions. Breast-conserving treatment has been established as the standard surgical procedure for primary breast cancer and fits to the preferences of most breast cancer patients concerning oncological safety and aesthetic outcome. Conclusions: Breast-conserving treatment is safe. Nonetheless, the preferences of the individual patients in their consideration of breast conservation versus mastectomy should be integrated into routine treatment decisions.


Sign in / Sign up

Export Citation Format

Share Document